Quantcast

Latest radiation poisoning Stories

2008-09-16 12:00:50

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (DHHS) has awarded the Company a contract under the Broad Agency Announcement titled, "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation," for selected tasks in the advanced development of Protectan CBLB502. The total contract...

2008-09-15 09:00:58

Cleveland BioLabs, a drug discovery and development company, has received a $774,183 grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic damage from radiation exposure. The grant program, medical countermeasures to enhance platelet regeneration and increase survival following radiation exposure, is funded through the Project BioShield Act...

2008-09-12 09:00:51

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it has been awarded a $774,183 grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), to further study certain mitigating properties of Protectan CBLB502 in the context of hematopoietic (blood/bone marrow) damage from radiation exposure. The grant program, Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure, is...

2008-08-07 09:01:05

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today the allowance from the U.S. Food and Drug Administration (FDA) to begin Phase I clinical trials in human volunteers with Protectan CBLB502, a drug under development for the treatment for Acute Radiation Syndrome (ARS). Protectan CBLB502 is being developed under the FDA's animal efficacy rule to treat radiation injury following exposure to radiation from nuclear or radiological weapons, or from nuclear accident. This approval pathway...

2008-07-08 09:01:11

Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced today that its first patent for Protectan CBLB502 was granted by the Eurasian Patent Organization (EAPO), which includes nine member countries. This patent covers the method of protecting a mammal from radiation using flagellin or its derivatives, including Protectan CBLB502. Cleveland BioLabs has filed over twenty patent applications in the U.S. and internationally, around various properties of Protectan CBLB502 and related compounds,...

2008-04-09 12:00:53

Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it will submit Protectan CBLB502 for the Broad Agency Announcement (BAA) soliciting research and development proposals for "Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss, and Vascular Injury Resulting from Acute Exposure to Ionizing Radiation" published on March 6, by the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS). BARDA seeks to acquire...

6288f696923b7b62e92423142af241fb1
2005-10-29 09:51:59

Researchers are making a list: Which parts of an astronaut are most sensitive to solar flares? NASA -- Picture this: An astronaut, on the Moon, hunched down over a rock, hammer in hand, prospecting. Suddenly, over his shoulder, there's a flash of light on the sun. The radio crackles: "Explorer 1, come in. This is mission control." Explorer 1: "What's up?" Mission Control: "There's been a solar flare, a big one. You need to take cover. The radiation storm could begin in as little as 10...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related